Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2006

Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
DRUG

irinotecan hydrochloride

Trial Locations (51)

3052

Royal Children's Hospital, Parkville

5006

Women's and Children's Hospital, North Adelaide

6001

Princess Margaret Hospital for Children, Perth

10021

Memorial Sloan-Kettering Cancer Center, New York

10032

Columbia Presbyterian Hospital, New York

13210

State University of New York - Upstate Medical University, Syracuse

15213

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

27710

Duke Comprehensive Cancer Center, Durham

30322

Emory University Hospital - Atlanta, Atlanta

48201

Children's Hospital of Michigan, Detroit

53226

Midwest Children's Cancer Center, Milwaukee

54301

CCOP - Green Bay, Green Bay

55905

Mayo Clinic Cancer Center, Rochester

60614

Children's Memorial Hospital, Chicago, Chicago

63104

Cardinal Glennon Children's Hospital, St Louis

64108

Children's Mercy Hospital, Kansas City

72205

University of Arkansas for Medical Sciences, Little Rock

76104

Cook Children's Medical Center - Fort Worth, Fort Worth

77030

Baylor College of Medicine, Houston

80218

Children's Hospital of Denver, Denver

84112

Huntsman Cancer Institute, Salt Lake City

92868

Children's Hospital of Orange County, Orange

94304

Lucile Packard Children's Hospital at Stanford, Palo Alto

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

91010-3000

Cancer Center and Beckman Research Institute, City of Hope, Duarte

92093-0658

University of California San Diego Cancer Center, La Jolla

90027-0700

Children's Hospital Los Angeles, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

94143-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

20010-2970

Children's National Medical Center, Washington D.C.

32610-100277

Shands Hospital and Clinics, University of Florida, Gainesville

46202-5289

Indiana University Cancer Center, Indianapolis

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

02111

Boston Floating Hospital Infants and Children, Boston

02115

Dana-Farber Cancer Institute, Boston

48109-7821

Mott Children's Hospital, Ann Arbor

39216-4505

University of Mississippi Medical Center, Jackson

07601

Hackensack University Medical Center, Hackensack

14263-0001

Roswell Park Cancer Institute, Buffalo

45229-3039

Children's Hospital Medical Center - Cincinnati, Cincinnati

29425-0721

Medical University of South Carolina, Charleston

38105-2794

Saint Jude Children's Research Hospital, Memphis

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

75235-9154

Simmons Cancer Center - Dallas, Dallas

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

78284-7811

University of Texas Health Science Center at San Antonio, San Antonio

53792-0001

University of Wisconsin Hospital and Clinics, Madison

M5G 1X8

Hospital for Sick Children, Toronto

H3H 1P3

McGill University Health Center - Montreal Children's Hospital, Montreal

H3T 1C5

Hopital Sainte Justine, Montreal

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT00008424 - Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants | Biotech Hunter | Biotech Hunter